<DOC>
	<DOCNO>NCT01689688</DOCNO>
	<brief_summary>The purpose study evaluate serial change neointimal coverage everolimus-eluting stent implantation 3- , 6- 12-months OCT examination .</brief_summary>
	<brief_title>Healing Response Everolimus-eluting Stent Implantation ; Serial Assessment With opticaL Coherence Tomography</brief_title>
	<detailed_description>Late late stent thrombosis current main issue introduction drug-eluting stent .Possible cause stent thromboses include thrombus formation result delay neointimal coverage , spasms occur distal end stent implantation site , positive remodel coronary artery cause local immune reaction paclitaxel rapamycin , vascular endothelial damage induce polymer . For BMS , neointimal coverage begin within first one month stent implantation almost complete three month . For DES , sirolimus elute stent ( SES ) example , neointimal coverage markedly delay stent implantation expose stent strut may largely attributable occurrence late stent thrombosis . On hand , everolimus elute stent ( EES ) , thinner stent strut layer improve polymer biocompatibility , report earlier normal neointimal coverage achieve compare first-generation DESs , SES paclitaxel elute stent ( PES ) . These finding suggest coverage vascular endothelium differs among different DES platform . Optical coherence tomography ( OCT ) resolution 15 20 Î¼m , approximately 10 time high intravascular ultrasound ( IVUS ) . It therefore necessary use OCT accurately evaluate cross-sectional image stent strut cover vascular endothelium . However , study report result continuous observation evaluation EES cover endothelium . Therefore , investigator investigate time course neointimal coverage EES detailed evaluation OCT neointimal coverage 3 , 6 , 12 month stent implantation .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Older 20 year old . 2 . Indication PCI . 3 . To agree review record clinical course research protocol . 4 . The patient eligible receive dual antiplatelet therapy least 6 month . 5 . Informed concent document sign patient . The patient correspond item time registration . 1 . The patient die research 2 . The patient Stent thrombosis research . 3 . Previous history pancytopenia , liver function , renal dysfunction , hypersensitive history drug . 4 . Low ejection fraction ( LVEF &lt; =30 % ) , impaired liver function , renal dysfunction ( eGFR &lt; =30 ) 5 . The patient exclude safety thiazolidine derivative . lesion exclusion criterion 1. leave main artery 2. severe calcification 3. stent restenosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>